China-Hospeq 2026, China International Hospital Construction, Equipment & Management Exhibition, was held at the China National Convention Center in Beijing from August 14 to 16, 2026. During the exhibition, Snibe showcased its integrated intelligent laboratory solutions built around SATLARS T8 and SATLARS mini T8. The company also hosted the International Symposium on Laboratory Medicine on August 15, bringing together 12 leading experts from five countries worldwide to discuss cutting-edge trends in laboratory diagnostics.

▍Dual Flagship TLA Solutions Unveiled to Pioneer a New Model for Intelligent Laboratories

At the exhibition, Snibe presented its self-developed SATLARS T8 and SATLARS mini T8 total laboratory automation (TLA) solutions as well as multidisciplinary laboratory diagnostic solutions, demonstrating the company’s core technological strengths in total laboratory automation and intelligent laboratory development.

Launched by Snibe in 2024, SATLARS T8 is an intelligent TLA solution featuring stable performance and high operational efficiency. More than 300 systems have been deployed globally to date. It is primarily designed for high-throughput testing environments including large tertiary hospitals and independent medical laboratories, fully meeting demanding clinical requirements for heavy workloads and high testing precision.

SATLARS mini T8 is a compact integrated TLA solution tailored for small and medium-sized hospitals, satellite laboratories and growing independent testing providers. With a small footprint and compelling cost-performance ratio, it enables mid- and grassroots healthcare institutions to deploy industry-leading end-to-end TLA workflows, supporting laboratories of all tiers to cut costs, boost efficiency and advance digital transformation.

Building on its dual flagship TLA portfolio, Snibe drives the shift of laboratory development from “automation” to “intelligence”. The company embeds digital capabilities including intelligent scheduling, multidisciplinary data integration and smart quality control into TLA lines to improve end-to-end laboratory efficiency and testing accuracy, living up to its brand ethos: Beyond Automation, Towards Excellence.

▍Expanding Global Partnerships: Snibe Signs MOU on Academic Research with Nepalese Institution

On the opening day of the exhibition, Snibe further expanded its global academic footprint by signing a Memorandum of Understanding (MOU) on research and academic cooperation with Madan Bhandari Academy of Health Sciences (MBAHS), Nepal. Both parties will establish a long-term strategic partnership to conduct in-depth collaboration on research innovation and technical exchange in laboratory medicine, supporting the standardized and high-quality development of laboratory medicine across Nepal.

Ms. Lucy Liu, the Vice President of Snibe, and Mr. Bhim Sagar Guragain, Registrar of MBAHS, signed the MOU on behalf of their respective organizations. Prof. Mario Plebani, past President of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), attended the signing ceremony as a witness, endorsing this cross-border academic partnership.

▍Academic Forum Gathers Experts from Seven Nations to Strengthen Global Laboratory Medicine Exchange

Hosted by Snibe, the International Symposium on Laboratory Medicine took place at the China National Convention Center in Beijing from 13:30 to 17:20 on August 15. Ms. Shao Meng, Deputy Director of the International Exchange and Cooperation Center of the National Health Commission of China, delivered the opening address. The symposium featured two sessions: Resetting Standards, Consolidating Quality Foundations and Precision Testing and Disciplinary Innovation. It assembled 12 distinguished specialists from five countries — China, Italy, Saudi Arabia, Turkey and Nepal — who shared the latest academic findings and real-world clinical experience.

▍Upholding Its Mission: Empowering Global Healthcare Through Made-in-China Innovation

With over 30 years of expertise in in-vitro diagnostics, Snibe regards advancing global laboratory medicine as a core corporate social responsibility. The company advances its international outreach across products, technologies and academic exchange. By fostering long-term ties with top medical schools and renowned specialists worldwide, Snibe builds sustainable collaboration platforms and works with global peers to drive industry innovation.

“Making diagnostic testing more accessible for patients” stands as both Snibe’s brand commitment and long-term corporate vision. Moving forward, drawing on its independent manufacturing capacity and AI-powered intelligent technologies, Snibe will continue developing accurate, efficient and accessible laboratory diagnostic solutions. The company aims to help healthcare providers worldwide lift operational performance and extend high-quality diagnostic services to more patients.